Last reviewed 2026-04-23 · How we verify

TEV-48125

TEV-48125 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5.

TEV-48125 is a selective, reversible inhibitor of the sodium-activated potassium channel Nav1.5. Used for Atrial fibrillation for stroke prevention.

At a glance

Mechanism of action

By inhibiting Nav1.5, TEV-48125 is expected to reduce the abnormal electrical activity in the heart that can lead to atrial fibrillation. This mechanism of action is thought to be responsible for the therapeutic effects of TEV-48125 in treating atrial fibrillation.

Approved indications

• Atrial fibrillation for stroke prevention

Common side effects

• Nausea
• Headache
• Dizziness

Key clinical trials

• A Randomized, Double-Blind, Placebo-Controlled Study With an Open-Label Period on Efficacy and Safety of Fremanezumab in Chinese Adults With Migraine (PHASE3)
• Fremanezumab Compassionate Use Program for Pediatric Patients
• A Study to Evaluate the Efficacy and Safety of Fremanezumab for Preventive Treatment of Migraine in Patients With Major Depressive Disorder (PHASE4)
• Long-term Safety and Tolerability of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Migraine (PHASE3)
• A Study to Test if Fremanezumab Reduces Headache in Participants With Posttraumatic Headache (PTH) (PHASE2)
• To Assess Pharmacokinetics, Safety and Tolerability of TEV-48125 in Japanese and Caucasian Healthy Subjects After a Single Subcutaneous (SC) Administration of TEV-48125 (PHASE1)
• Comparing Efficacy and Safety of 2 Dose Regimens of Subcutaneous Administration of TEV-48125 Versus Placebo for the Preventive Treatment of Chronic Migraine (PHASE3)
• An Efficacy and Safety Study of Fremanezumab in Adults With Migraine (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.